Compare Mesoblast Limited (MESO) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs MINISO Group Holding Ltd — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while MINISO Group Holding Ltd trades at $12.46 (market cap $3.87B). The key difference: MINISO Group Holding Ltd is the larger of the two by market cap, and MINISO Group Holding Ltd pays a 5.21% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MNSO | |
|---|---|---|
Market Cap | $2.17B | $3.87B |
Sector | Technology | Technology |
52-Week High | $20.96 | $26.63 |
52-Week Low | $12.88 | $11.30 |
Enterprise Value | $2.17B | $4.54B |
Dividend Yield | — | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
MNSO trades at $12.79, up 0.31% today, with a bullish technical signal driven by moving averages. The stock shows strong fundamentals with a P/E of 12.98 and net income margin of 8.98% for 2026. Recent Q1 2026 earnings beat expectations with EPS of $0.591, and the company announced a HK$2 billion share repurchase program on June 29, 2026, signaling confidence.
Outlook is positive given earnings momentum and valuation support, but risks include margin pressure from overseas expansion costs and mixed quarterly performance. Analyst consensus is 75% buy, though one sell rating highlights growth execution concerns. The stock remains a growth play with manageable valuation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
